Navigation Links
Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Date:7/22/2008

Cancer Center.

"After years of methodical design and development to optimize our products, these results in end-stage liver cancer patients clearly validate our breakthrough product class. The clinical and mechanistic results were predicted based on extensive lab testing of JX-594. This peer-reviewed publication in Molecular Therapy represents a major clinical and scientific advance for JX-594," said David Kirn, M.D., President & CEO of Jennerex. "As always, we thank the doctors, the patients and their families, and our partners at Green Cross who have all pioneered this treatment with us."

Phase I-II Liver Cancer Study

As previously reported, 14 patients with a variety of treatment-refractory cancer types (e.g. liver, colon, lung) in the liver were treated every three weeks with JX-594 by ultrasound-guided intratumoral injection. Patients had advanced cancers that had failed all available therapies and were therefore considered terminal. Treatment was well-tolerated during dose-escalation up to the maximum-tolerated dose, with the expected mild to moderate flu-like symptoms; no severe toxicities due to treatment were reported up to these doses. Cancer destruction and objective evidence for efficacy were reported in the majority of patients, including all three with primary liver cancer and patients with lung and colon cancers. Tumor responses were achieved in evaluable patients by objective criteria including RECIST (Response Evaluation Criteria in Solid Tumor) (response in 30 percent of patients, stable disease in 60 percent of patients) and Choi criteria (response in 80% of patients). Tumor responses were associated with long-term survival in many patients, including four who survived for 11 to over 18 months. Mechanism-of-action of JX-594 was validated in patients by demonstration of tumor-specific replication and tissue destruction with JX-594, in addition to high-level active expression of the GM-CSF protein in the blood of patients. Thes
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
2. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
6. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
11. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015  On May ... will convene in Santa Monica, CA ... on Lung-Sparing Therapies for Malignant Pleural Mesothelioma (MPM), ... exposure to asbestos and commonly affects the lining ... co-hosted by UCLA and the Pacific Mesothelioma Center ...
(Date:3/31/2015)... - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), a ... products and a licensed producer ("LP") to cultivate marijuana ... Canada ) ("MMPR"), is pleased to announce that ... District of Saanich confirming the ... allows for commercial distribution of medical marijuana under the ...
(Date:3/31/2015)... 31, 2015 ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... Hydrochloride 150mg, 225mg and 300mg oral tablets, indicated for ... US market for Propafenone Hydrochloride 150mg, 225mg and 300mg ... Arthur S. Przybyl , President and ... the launch of our fourth product from the portfolio ...
Breaking Medicine Technology:Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 2Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 3Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 4T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 2T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 3ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3
... April 28 Omnicell, Inc ., (Nasdaq: ... acute healthcare facilities, today announced that KLAS , a ... with the Category Leader distinction for Medication Order Management Systems ... Software & Professional Services report. OmniLinkRx received ...
... 27 Today, the BioMedix TRAKnet software suite was granted ... is the only company to receive the APMA Seal of Acceptance ... , , ... for our member podiatrists because it integrates day to day activities ...
Cached Medicine Technology:Omnicell's OmniLinkRx Honored With KLAS Award for Product Leadership 2Omnicell's OmniLinkRx Honored With KLAS Award for Product Leadership 3Omnicell's OmniLinkRx Honored With KLAS Award for Product Leadership 4BioMedix Receives Clinical Approval for TRAKnet Software 2BioMedix Receives Clinical Approval for TRAKnet Software 3
(Date:3/31/2015)... 31, 2015 St. Joseph Medical Center ... of leading healthcare systems, major physician groups and health ... the benefit of patients. The health information exchange provides ... well coordinated care throughout the continuum of services a ... tradition of providing services to a broad cross section ...
(Date:3/31/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... Merchandise show in Orlando. At the show, former LPGA ... Will was interviewed and she shared the life-changing physical ... she began integrating the Juvent Pro Micro-Impact Platform™ into ... so instrumental to her chronic back pain recovery that ...
(Date:3/31/2015)... An individual’s meniscus (cushion in the ... the leg providing stability, load bearing and preservation of ... Specialty Day meeting of the American Orthopaedic Society for ... determine the potential for biologic healing following a meniscus ... healing of meniscus tears when a root repair is ...
(Date:3/31/2015)... March 31, 2015 Yesco Electrical ... Youngstown, Ohio in 1987. This successful business ... with not just customer satisfaction, but advanced technology. ... to the well-stocked arsenal of Yesco is the ... Green Technology® (AGT). The patented environmental disinfection system ...
(Date:3/31/2015)... Lake, Wis. (PRWEB) March 31, 2015 ... their patients and a faster return on their investment, ... body composition analyzer at Obesity Medicine 2015, April 8-12 ... for busy weight loss centers and medical offices, Rice ... as a health assessment tool. Obesity Medicine 2015 delivers ...
Breaking Medicine News(10 mins):Health News:St. Joseph Medical Center Joins Other Leading Healthcare Systems Participating in Greater Houston Healthconnect 2Health News:Former LPGA Tour Winner Maggie Will Discovers The Juvent Micro-Impact Platform as a Pain Relief Breakthrough and Performance Enhancer 2Health News:Former LPGA Tour Winner Maggie Will Discovers The Juvent Micro-Impact Platform as a Pain Relief Breakthrough and Performance Enhancer 3Health News:New Way to Evaluate Meniscus Tear Outcomes 2Health News:American Green Technology® Signs Exclusive Agreement to Distribute Health Risk Management System in Midwest 2Health News:Rice Lake Weighing Systems’ Body Composition Analyzer On Display at Obesity Medicine 2015 2
... caused by the acne drug Isotretinoin? – Asks a debate ... effective treatment for severe acne - a condition, which can ... also cause severe birth defects if pregnant women take it. ... pregnant women from taking the drug, and to prevent women ...
... Medical Center have developed a substance that inhibits the ... The agent, a novel calpain inhibitor, can be administered ... naturally found in the human body. Inappropriate activation of ... autoimmune diseases such as MS. It is known to ...
... a form of Parkinson's disease (PD) wreaks its damage by ... found. They have pinpointed the malfunction of the protein made ... it affects neurons, ultimately leading to their death. The loss ... and loss of connections among such neurons is an early ...
... reportedly swallowed tiny magnets that fell off toys had ... Product Safety Commission has// ordered a major recall of ... Mattel.,Mattel is an El Segundo-based toy manufacturer. ... complaints reporting that small magnets fell out of the ...
... stem cells taken from adult pigs’ healthy heart tissue and ... done to those organs by lab-induced heart attacks. Pigs’ hearts ... in such research. ,Following up on previous studies, ... heart tissue no bigger than a grain of rice within ...
... and Department of Pharmaceutical Chemistry, ASN Pharmacy College, ... leaves. The objective of the present study was ... of leaves of Plumeria Acuminata on carrageenan, dextran, ... oedema models. ,Plumeria Acuminata belongs to ...
Cached Medicine News:Health News:Parkinson's Mutation Stunts Neurons 2Health News:Pig Stem Cells Show Promise in Repairing Animals’ Heart Attack Damag 2Health News:Pig Stem Cells Show Promise in Repairing Animals’ Heart Attack Damag 3Health News:Anti Inflammatory Evaluation Of Plumeria Acuminata Leaves 2
... Activa Parkinson's Control Therapy uses ... treat some of the most disabling ... Parkinson's Control Therapy is a safe ... many Parkinson's patients. Activa Therapy controls ...
... The Sony LMD-2140MD is a medical-grade, 21" ... The LMD2140MD incorporates a superb-quality LCD panel ... brightness, contrast and color depth. This monitor ... signal input capabilities for analog or digital, ...
... The Sony LMD-181MD medical grade flat panel is ... LCD is perfect for endoscopy, surgery, radiology and ultrasound. ... or used on a overhead surgical arm. It allows ... video board and also has a built in VGA ...
Resorbable fixation system 1.5/2.0....
Medicine Products: